Novartis AG (0QLR.IL)
| Previous close | 80.92 |
| Open | 81.90 |
| Bid | 79.86 x N/A |
| Ask | 83.88 x N/A |
| Day's range | 81.63 - 82.19 |
| 52-week range | 72.84 - 89.28 |
| Volume | |
| Avg. volume | 1,300,263 |
| Market cap | 181.146B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 7.80 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.10 (3.90%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower d
- Globe Newswire
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD 100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and USD 150 million for next-generation antimalarials and a new formulation for babies under 5kg with malariaAround the world, 1.7 billion people suffer from NTDs1, and there are 241 million cases of malaria2 Base
- Globe Newswire
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with solid tumors that have a BRAF V600E mutation1,2 Approval supported by results from Phase II ROAR and NCI-MATCH studies demonstrating overall response rates up to 80% in patients with BRAF V600E solid tumors1,2 BRAF mutations drive tumor growth across more than 20 tumor types, including thyroid, brain
